{"id":"ak112-with-scrt","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AK112 with SCRT works by binding to the molecular target, which leads to a cascade of downstream effects that ultimately result in the desired therapeutic outcome.","oneSentence":"AK112 with SCRT is a small molecule that targets the molecular target to exert its therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:18:45.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown"}]},"trialDetails":[{"nctId":"NCT07162714","phase":"PHASE2","title":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-09-01","conditions":"Rectal Cancer, Radiation, AK112","enrollment":30},{"nctId":"NCT06718543","phase":"PHASE2","title":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"fan li","startDate":"2025-02-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT06802666","phase":"PHASE2","title":"Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-10-16","conditions":"Locally Advanced Rectal Cancer, Neoadjuvant Therapy","enrollment":45},{"nctId":"NCT06760520","phase":"PHASE2","title":"Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-01-20","conditions":"Locally Advanced Rectal Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AK112 with SCRT","genericName":"AK112 with SCRT","companyName":"fan li","companyId":"fan-li","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK112, also known as Ivonescimab, is an antibody used in the treatment of rectal cancer. It is being studied in a clinical trial, STAR, as a follow-up treatment after short-course radiotherapy for mid-low rectal cancer.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}